Biosimilars Market is expected to reach USD 10.90 billion by 2021

Tuesday, May 23, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 23, 2017 /PRNewswire/ --

Highlights

  • Biosimilars Market by Product
    (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application (Oncology, Blood Disorders) - Global Forecast To 2021.
  • The global
    biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region.
  • On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.
  • On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations.
  • The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period.
  • On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications.
  • In 2016, the oncology segment is expected to account for the largest share of the market.

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application (Oncology, Blood Disorders) - Global Forecast To 2021

The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region.

On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest share of the biosimilars market, in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving growth in this market.

On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations. The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period.

On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. In 2016, the oncology segment is expected to account for the largest share of the market.

Geographically, the biosimilars market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). Growth in the European market is attributed to the growing pressure to curtail healthcare costs, patent expiry of biologics & the arrival of new biosimilars, and the rising incidence of chronic disorders.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market. The report analyses the biosimilars market by product, manufacturing type, and application.

- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the biosimilars market

- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market

- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars products across geographies

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

Read the full report: http://www.reportlinker.com/p04604343/Biosimilars-Market-by-Product-Manufacturing-Application-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: [email protected] US:(339) 368 6001 Intl:+1 339 368 6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilars-market-is-expected-to-reach-usd-1090-billion-by-2021-300462189.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store